A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
about
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.Cell internalization of 7-ketocholesterol-containing nanoemulsion through LDL receptor reduces melanoma growth in vitro and in vivo: a preliminary report.Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.
P2860
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
@en
type
label
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
@en
prefLabel
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
@en
P2093
P2860
P356
P1433
P1476
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
@en
P2093
Aisha Shamas-Din
Danny V Jeyaraju
Guri Giaever
Marcela Gronda
Mark D Minden
Neil MacLean
Rose Hurren
Xiaoming Wang
P2860
P304
49777-49785
P356
10.18632/ONCOTARGET.10446
P407
P577
2016-07-06T00:00:00Z